Skip to main content
. 2021 Dec 20;7:399. doi: 10.1038/s41420-021-00766-9

Fig. 4. NLRP3 inflammasome exerts oncogenic activity by activating caspase-1 in PCa cell lines.

Fig. 4

A Western blotting analysis verified the transfection efficiency of NLRP3 after sh-NLRP3 + recombinant protein caspase-1 or ov-NLRP3 + Z-YVAD-FMK in PC3 and LNCaP cell lines, respectively. B qRT-PCR analysis verified the transfection efficiency of NLRP3 after sh-NLRP3 + recombinant protein caspase-1 or ov-NLRP3 + Z-YVAD-FMK in PC3 and LNCaP cell lines, respectively. C The expression of IL-1β and IL-18 in the supernatant and lysate of PC3 and LNCaP cell lines were significantly decreased in sh-NLRP3 + recombinant protein caspase-1, not in sh-NLRP3 alone. D The expression of IL-1β and IL-18 in the supernatant and lysate of PC3 and LNCaP cell lines were significantly decreased in ov-NLRP3 + Z-YVAD-FMK, not in ov-NLRP3 alone. E CCK-8 assay detected the proliferation of PCa after sh-NLRP3 + recombinant protein caspase-1 or ov-NLRP3 + Z-YVAD-FMK in PC3 and LNCaP cell lines, respectively. F Transwell assay was used to detect the migration ability after sh-NLRP3 + recombinant protein caspase-1 or ov-NLRP3 + Z-YVAD-FMK in PC3 and LNCaP cell lines, respectively (magnification: ×40). G TUNEL assay was used to detect the apoptosis after sh-NLRP3 + recombinant protein caspase-1 or ov-NLRP3 + Z-YVAD-FMK in PC3 and LNCaP cell lines, respectively (magnification: ×40). H Western Blot was used to detect the expression level of NLRP3 and caspase-1 after sh-NLRP3 + recombinant protein caspase-1 or ov-NLRP3 + Z-YVAD-FMK in PC3 and LNCaP cell lines, respectively. Data are average ± SD, *p < 0.05, **p < 0.01.